MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
March 9, 2026
Biotechnology
-
-
Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026
March 9, 2026
-
Solid Biosciences Announces Oversubscribed $240 Million Private Placement
March 6, 2026
-
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 6, 2026
-
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
March 6, 2026
-
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
March 5, 2026
-
CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab
March 5, 2026
-
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million
March 4, 2026
-
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program
March 4, 2026
-
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
March 4, 2026
-
INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
March 4, 2026
-
BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy
March 4, 2026
-
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
March 3, 2026
-
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
March 3, 2026
-
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
March 2, 2026
-
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress
March 2, 2026